Download PDF
Dtsch Med Wochenschr 2016; 141(1): 51-57
DOI: 10.1055/s-0041-102893
Fachwissen
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Update HIV und Neurologie

Update HIV and neurology
Katrin Hahn
1   Klinik für Neurologie, Charité Berlin
,
Matthias Maschke
2   Klinik für Neurologie, Krankenhaus der Barmherzigen Brüder Trier
,
Christian Eggers
3   Abteilung für Neurologie, Krankenhaus der Barmherzigen Brüder Linz
,
Ingo Wilhelm Husstedt
4   Praxis im Krankenhaus Maria Frieden, Telgte / Medizinische Fakultät der Westfälischen Wilhelms Universität Münster
,
Gabriele Arendt
5   Klinik für Neurologie, Universitätsklinikum Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
28 December 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Fortschritte der antiretroviralen Therapie haben die HIV-Infektion zu einer chronischen Krankheit gemacht. Der Übersichtsartikel fasst zusammen, was ein Leben mit HIV aus neurologischer Sicht über Jahrzehnte hinweg für die Betroffenen bedeutet. Neben klinischen und pathophysiologischen Aspekten des HIV-assoziierten kognitiven Defizits (HAND) werden auch periphere HIV-Manifestationen beleuchtet. Der Artikel berücksichtigt Komorbiditäten wie die in der Inzidenz ansteigende Neurolues, sowie die Hepatitis C, da beide durch ihr Interaktionsspektrum mit dem HI-Virus insbesondere für den Neurologen von großem Interesse sind.

Abstract

With modern antiretroviral drug regimens, HIV-infected people are living longer and HIV has transformed into a chronic illness. The review summarizes pathophysiological as well as clinical aspects of a chronic infection from a neurological point of view including neurocognitive impairment, depression, neuropathies and myopathies. It also draws attention to comorbidities such as syphilis and hepatitis C. They are of particular neurological interest because of the interaction of the pathogens.

Schlüsselwörter

NeuroAIDS - HAND - Depression - Neurolues - Hepatitis C

Keywords

NEUROAIDS - HAND - depression - neurolues - hepatitis C
 

  • Literatur

  • 1 Triant VA. HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis 2012; 205 ((Suppl 3)) 355-361
    CrossrefPubMedGoogle Scholar
  • 2 Snider WD, Simpson DM, Nielsen S et al. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 1983; 14: 403-418
    CrossrefPubMedGoogle Scholar
  • 3 Gray F, Scaravilli F, Everall I et al. Neuropathology of early HIV-1 infection. Brain Pathol 1996; 6: 1-15
    CrossrefPubMedGoogle Scholar
  • 4 Marra CM, Maxwell CL, Collier AC et al. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. BMC Infect Dis 2007; 7: 37-37
    CrossrefPubMedGoogle Scholar
  • 5 Budka H. Neuropathology of human immunodeficiency virus infection. Brain Pathol 1991; 1: 163-175
    CrossrefPubMedGoogle Scholar
  • 6 Shaw GM, Harper ME, Hahn BH et al. HTLV-III infection in brains of children and adults with AIDS encephalopathy. Science 1985; 227: 177-182
    CrossrefPubMedGoogle Scholar
  • 7 Everall IP, Heaton RK, Marcotte TD et al. Cortical synaptic density is reduced in mild to moderate HIV neurocognitive disorder. Brain Pathol 1999; 9: 209-217
    PubMedGoogle Scholar
  • 8 Eggers C, Hertogs K, Stuerenburg HJ et al. Delayed CNS virus suppression during HAART is associated with HIV encephalopathy, but not with viral drug resistance or poor CNS drug penetration. AIDS 2003; 17: 1897-1906
    CrossrefPubMedGoogle Scholar
  • 9 Eggers C, Muller O, Thordsen I et al. Genetic shift of env V3 loop viral sequences in patients with HIV-associated neurocognitive disorder during antiretroviral therapy. J Neurovirol 2013; 19: 523-530
    CrossrefPubMedGoogle Scholar
  • 10 McArthur JC. Dementia, neuropathy, and HIV. An interview with Justin C. McArthur, MB, BS, MPH. Interview by Mark Mascolini. J Int Assoc Physicians AIDS Care 1996; 2: 27-34
    PubMedGoogle Scholar
  • 11 Tozzi V, Balestra P, Serraino D et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses 2005; 21: 706-713
    CrossrefPubMedGoogle Scholar
  • 12 Antinori A, Arendt G, Becker JT et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789-1799
    CrossrefPubMedGoogle Scholar
  • 13 Power C, Selnes OA, Grim JA et al. HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 273-278
    CrossrefPubMedGoogle Scholar
  • 14 Sacktor NC, Wong M, Nakasujja N et al. The International HIV dementia scale: a new rapid screening test for HIV dementia. Aids 2005; 19: 1367-1374
    PubMedGoogle Scholar
  • 15 Zipursky AR, Gogolishvili D, Rueda S et al. Evaluation of brief screening tools for neurocognitive impairment in HIV / AIDS: a systematic review of the literature. AIDS 2013; 27: 2385-2401
    CrossrefPubMedGoogle Scholar
  • 16 Ciccarelli N, Fabbiani M, Di Giambenedetto S et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011; 76: 1403-1409
    CrossrefPubMedGoogle Scholar
  • 17 Clifford DB, Evans S, Yang Y et al. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097 s). HIV Clin Trials 2009; 10: 343-355
    CrossrefPubMedGoogle Scholar
  • 18 Mind Exchange Working Group Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis 2013; 56: 1004-1017
    CrossrefPubMedGoogle Scholar
  • 19 McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005; 4: 543-555
    CrossrefPubMedGoogle Scholar
  • 20 Marshall DW. HIV penetration of the BBB. Neurology 1988; 38: 1000-1001
    CrossrefPubMedGoogle Scholar
  • 21 The Mind Exchange Working Group Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis 2013; 56: 1004-1007
    CrossrefPubMedGoogle Scholar
  • 22 Hagberg L, Cinque P, Gisslen M et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 2010; 7: 15-15
    CrossrefPubMedGoogle Scholar
  • 23 Abdulle S, Mellgren A, Brew BJ et al. CSF neurofilament protein (NFL) – a marker of active HIV-related neurodegeneration. J Neurol 2007; 254: 1026-1032
    CrossrefPubMedGoogle Scholar
  • 24 Letendre S, Marquie-Beck J, Capparelli E et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65-70
    CrossrefPubMedGoogle Scholar
  • 25 Gorman JM, Mayeux R, Stern Y et al. The effect of zidovudine on neuropsychiatric measures in HIV-infected men. Am J Psychiatry 1993; 150: 505-507
    CrossrefPubMedGoogle Scholar
  • 26 Croteau D, Best BM, Letendre S et al. Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50 % inhibitory concentration. AIDS 2012; 26: 890-893
    CrossrefPubMedGoogle Scholar
  • 27 Garvey L, Nelson M, Latch N et al. CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. J Antimicrob Chemother 2012; 67: 206-212
    CrossrefPubMedGoogle Scholar
  • 28 Croteau D, Letendre S, Best BM et al. Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother 2010; 54: 5156-5160
    CrossrefPubMedGoogle Scholar
  • 29 Yilmaz A, Price RW, Gisslen M. Antiretroviral drug treatment of CNS HIV-1 infection. J Antimicrob Chemother 2012; 67: 299-311
    CrossrefPubMedGoogle Scholar
  • 30 Calcagno A, Cusato J, Simiele M et al. High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. J Antimicrob Chemother 2014; 69: 241-245
    CrossrefPubMedGoogle Scholar
  • 31 Calcagno A, Simiele M, Alberione MC et al. Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control. Clin Infect Dis 2015; 60: 311-317
    CrossrefPubMedGoogle Scholar
  • 32 Dahl V, Lee E, Peterson J et al. Raltegravir treatment intensification does not alter cerebrospinal Fluid HIV-1 Infection or Immunoactivation in subjects on suppressive therapy. J Infect Dis 2011; 204: 1936-1945
    CrossrefPubMedGoogle Scholar
  • 33 Schifitto G, Navia BA, Yiannoutsos CT et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. Aids 2007; 21: 1877-1886
    CrossrefPubMedGoogle Scholar
  • 34 Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001; 158: 725-730
    CrossrefPubMedGoogle Scholar
  • 35 Bouhnik AD, Preau M, Vincent E et al. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther 2005; 10: 53-61
    PubMedGoogle Scholar
  • 36 Rivera-Rivera Y, Garcia Y, Toro V et al. Depression correlates with increased plasma levels of inflammatory cytokines and a dysregulated oxidant / antioxidant balance in HIV-1-infected subjects undergoing antiretroviral therapy. J Clin Cell Immunol 2014; 5: 1000276-1000276
    PubMedGoogle Scholar
  • 37 Ickovics JR, Hamburger ME, Vlahov D et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001; 285: 1466-1474
    CrossrefPubMedGoogle Scholar
  • 38 Husstedt IW, Arendt G. HIV und ZNS: Management neurologischer Erkrankungen. 2. Aufl Königswinter: Immedis; 2012
    Google Scholar
  • 39 [Anonym] Depression is common among AIDS patients. Psych consult often is necessary. AIDS Alert 2002; 17: 153-154
    PubMedGoogle Scholar
  • 40 Colibazzi T, Hsu TT, Gilmer WS. Human immunodeficiency virus and depression in primary care: a clinical review. Prim Care Companion J Clin Psychiatry 2006; 8: 201-211
    CrossrefPubMedGoogle Scholar
  • 41 Cohen MA, Gorman JM. Comprehensive Textbook of AIDS Psychiatry. Oxford: Oxford University Press; 2008
    Google Scholar
  • 42 Robert-Koch-Institut Epidemiologisches Bulletin. Robert-Koch-Institut 2012; 48: 481-488
    PubMedGoogle Scholar
  • 43 Marra CM, Maxwell CL, Smith SL et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis 2004; 189: 369-376
    CrossrefPubMedGoogle Scholar
  • 44 RKI, Epidemiologisches Bulletin: Virushepatitis C im Jahr 2013 in Epidemiologisches Bulletin Nr. 31, RKI, Editor 2014: 275-288
  • 45 Robert-Koch-Institut Epidemiologisches Bulletin. Robert-Koch-Institut 2013; 30: 273-284
    PubMedGoogle Scholar
  • 46 Yaphe S, Bozinoff N, Kyle R et al. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex Transm Infect 2012; 88: 558-564
    CrossrefPubMedGoogle Scholar
  • 47 Martin-Thormeyer EM, Paul RH. Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev 2009; 19: 215-231
    CrossrefPubMedGoogle Scholar
  • 48 Devlin KN, Gongvatana A, Clark US et al. Neurocognitive effects of HIV, hepatitis C, and substance use history. J Int Neuropsychol Soc 2012; 18: 68-78
    CrossrefPubMedGoogle Scholar
  • 49 Ryan EL, Morgello S, Isaacs K et al. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 2004; 62: 957-962
    CrossrefPubMedGoogle Scholar
  • 50 Hofmann WP, Sarrazin C, Zeuzem S. Current standards in the treatment of chronic hepatits C. Dtsch Arztebl Int 2012; 109: 352-358
    PubMedGoogle Scholar
  • 51 Hahn K, Husstedt IW. HIV-associated neuropathies. Nervenarzt 2010; 81: 409-417
    CrossrefPubMedGoogle Scholar
  • 52 Centner CM, Bateman KJ, Heckmann JM. Manifestations of HIV infection in the peripheral nervous system. Lancet Neurol 2013; 12: 295-309
    CrossrefPubMedGoogle Scholar
  • 53 Arenas-Pinto A, Bhaskaran K, Dunn D et al. The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial. Antivir Ther 2008; 13: 289-295
    PubMedGoogle Scholar
  • 54 Ellis RJ, Rosario D, Clifford DB et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol 2010; 67: 552-558
    CrossrefPubMedGoogle Scholar
  • 55 Hahn K, Robinson B, Anderson C et al. Differential effects of HIV infected macrophages on dorsal root ganglia neurons and axons. Exp Neurol 2008; 210: 30-40
    CrossrefPubMedGoogle Scholar
  • 56 Hahn K, Arendt G, Braun JS et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 2004; 251: 1260-1266
    CrossrefPubMedGoogle Scholar
  • 57 Wernicke JF, Pritchett YL, D’Souza DN et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67: 1411-1420
    CrossrefPubMedGoogle Scholar
  • 58 Simpson DM, Brown S, Tobias J.. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008; 70: 2305-2313
    CrossrefPubMedGoogle Scholar
  • 59 Martin C, Solders G, Sonnerborg A et al. Antiretroviral therapy may improve sensory function in HIV-infected patients: a pilot study. Neurology 2000; 54: 2120-2127
    CrossrefPubMedGoogle Scholar
  • 60 Brannagan TH, 3 rd Zhou Y. HIV-associated Guillain-Barre syndrome. J Neurol Sci 2003; 208: 39-42
    CrossrefPubMedGoogle Scholar
  • 61 Thornton CA, Latif AS, Emmanuel JC. Guillain-Barre syndrome associated with human immunodeficiency virus infection in Zimbabwe. Neurology 1991; 41: 812-815
    CrossrefPubMedGoogle Scholar
  • 62 Yombi JC, Vandercam B, Wilmes D et al. Osteonecrosis of the femoral head in patients with type 1 human immunodeficiency virus infection: clinical analysis and review. Clin Rheumatol 2009; 28: 815-823
    CrossrefPubMedGoogle Scholar
  • 63 Mary-Krause M, Billaud E, Poizot-Martin I et al. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy. Aids 2006; 20: 1627-1635
    CrossrefPubMedGoogle Scholar
  • 64 Cazanave C, Dupon M, Lavignolle-Aurillac V et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. Aids 2008; 22: 395-402
    CrossrefPubMedGoogle Scholar
  • 65 Gardner K, Hall PA, Chinnery PF et al. HIV treatment and associated mitochondria pathology: review of 25 years of in vitro, animal, and human studies. Toxicol Pathol 2014; 42: 811-822
    CrossrefPubMedGoogle Scholar